Center for Cancer and Immunology Research, Children's National Health System, The George Washington University, Washington, DC, United States.
Division of Oncology, Children's National Health System, Washington, DC, United States.
Front Immunol. 2018 Mar 19;9:556. doi: 10.3389/fimmu.2018.00556. eCollection 2018.
Patients with primary immunodeficiency disorders (PID) have an increased risk from acute and chronic Epstein-Barr Virus (EBV) viral infections and EBV-associated malignancies. Hematopoietic stem cell transplantation (HSCT) is a curative strategy for many patients with PID, but EBV-related complications are common in the immediate post-transplant period due to delayed reconstitution of T cell immunity. Adoptive T cell therapy with EBV-specific T cells is a promising therapeutic strategy for patients with PID both before and after HSCT. Here we review the methods used to manufacture EBV-specific T cells, the clinical outcomes, and the ongoing challenges for future development of the strategy.
原发性免疫缺陷病（PID）患者发生急性和慢性 EBV（Epstein-Barr Virus）病毒感染和 EBV 相关恶性肿瘤的风险增加。造血干细胞移植（HSCT）是许多 PID 患者的一种根治策略，但由于 T 细胞免疫重建延迟，HSCT 后即刻期 EBV 相关并发症很常见。在 HSCT 前后，使用 EBV 特异性 T 细胞的过继性 T 细胞治疗是 PID 患者有希望的治疗策略。在此，我们综述了 EBV 特异性 T 细胞的制备方法、临床结果以及该策略未来发展所面临的挑战。
